Aurobindo Pharma Limited has informed the Exchange regarding a press release dated December 21, 2024, titled "CuraTeQ Biologics receives approval for oncology biosimilar Bevqolva from UK s MHRA".
Aurobindo Pharma Limited has informed the Exchange regarding a press release dated December 21, 2024, titled "CuraTeQ Biologics receives approval for oncology biosimilar Bevqolva from UK s MHRA".